Pulido-Díaz N, Angulo-Álvarez DM, López-Ibarra M

Idioma: Español
Referencias bibliográficas: 11
Paginas: 59-62
Archivo PDF: 39.55 Kb.

RESUMEN

La necrólisis epidérmica tóxica y el síndrome de Stevens-Johnson son reacciones graves provocadas por medicamentos, que predominantemente afectan la piel y las membranas mucosas. Se describe la afección de 75 % de superficie corporal total en una mujer de 43 años de edad, a quien se le administró gammaglobulina intravenosa como tratamiento de elección, con resultados satisfactorios.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Wanat KA, Anadkat MJ, Klekotka PA. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole. J Am Acad Dermatol 2009;60(4):589-594.

2. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139(1):26-32.

3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129(1):92-96.

4. Ringheanu M. Toxic epidermal necrolysis in children. An update. Clin Pediatr 2000;39(12):687.

5. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007;56(2):181-200.

6. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol 2008;122(5):992-1000.

7. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139(1):33-36. Disponible en http://archderm.amaassn. org/cgi/content/full/139/1/33

8. Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 2007;87(3):206-218. Disponible en http://www.medicaljournals.se/acta/content/ ?doi=10.2340/00015555-0249

9. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139(1):26-32.

10. Trent JT, Fangchao M, Kerdel F, Fie S, French LE, Romanelli P, Kirsner RS. Dose of intravenous immunoglobulin and patient survival in SJS and toxic epidermal necrolysis. Expert Rev Dermatol 2007;2(3):299-303.

11. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006;97(3):272- 280.